Eli Lilly’s M&A Friday; Novartis’ TIGIT breakup; One big hire and one big exit; Reverse merger, shutdown and white flags; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

We’re just a few days away from un­veil­ing this year’s list of women blaz­ing tri­als in bio­phar­ma R&D. In ad­di­tion to an award cer­e­mo­ny in which you will get to hear snip­pets from our in­ter­view with hon­orees. I will be host­ing Fiona Mar­shall, pres­i­dent of the No­var­tis In­sti­tutes for Bio­Med­ical Re­search, for a fire­side chat, while my col­league Nicole De­Feud­is will mod­er­ate a pan­el with a trio of women lead­ers who are mak­ing their voic­es heard. We hope to see you there.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN